PDI2
Based on 1 Customer Validation
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
For research use only. We do not sell to patients.
- Purity: 99.00%
- CAS No.: 3110124-60-9
- Formula: C59H90N12O19
- Molecular Weight:1271.41
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
All Radionuclide-Drug Conjugates (RDCs) Isoforms
More
Biological Activity
[111In]In-PDI2 (0.195-50 nM; incubated on ice for 2 h) binds specifically to PSMA on LNCaP cells, with a Kd value of 22.8 nM[1].
[111In]In-PDI2 (37 kBq; incubated on ice for 2 h, incubated at 37°C for 0-4 h) shows an internalization rate of 38.9% in LNCaP cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PDI2 (5-10 kBq; i.v.; single dose) effectively inhibits the growth of PSMA-positive LNCaP prostate cancer xenografts with no obvious toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nu/nu (male, 5-6 weeks old)[1]
-
Dosage:111 kBq
-
Administration:i.v.; single dose
-
Result:Measured 20.74% ID/g tumor accumulation at 4-h postinjection; measured 25.47% ID/g tumor accumulation at 24-h postinjection; measured 13.54% ID/g tumor accumulation at 96-h postinjection; measured 52.31% ID/g renal uptake at 4-h postinjection; measured 4.85% ID/g renal uptake at 24-h postinjection; achieved 7.3 tumor-to-kidney radioactivity ratio.
Chemical Information
-
CAS No. 3110124-60-9
-
Appearance Solid
-
Molecular Weight 1271.41
-
Formula C59H90N12O19
-
Color White to off-white
-
Synonyms
PSMA-DOTA-PEI2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 1 mg/mL (0.79 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
PDI2 Related Classifications
Cat. No.: HY-P11591
Powered by Bioz
- PDI2
- 3110124-60-9
- PSMA-DOTA-PEI2
- PDI 2
- PDI-2
- Radionuclide-Drug Conjugates (RDCs)
- PSMA
- PSMA-positive LNCaP prostate cancer xenografts
- SPECT/CT
- prostate-specific membrane antigen
- metastatic castration-resistant prostate cancer
- prostate cancer
- prostate cancer cells
- targeted radionuclide therapy
- LNCaP cells
- clathrin-dependent endocytosis
- Inhibitor
- inhibitor
- inhibit